modelRivastigmine
Extends from Pharmacolibrary.Drugs.ATC.N.N06DA03.
Information
| name: | Rivastigmine | |
| ATC code: | N06DA03 | route: | oral |
| compartments: | 1 | |
| dosage: | 3 | mg |
| volume of distribution: | 1.8 | L |
| clearance: | 2.1 | L/h/kg |
| other parameters in model implementation | ||
Rivastigmine is a reversible cholinesterase inhibitor approved for the symptomatic treatment of mild to moderate dementia related to Alzheimer’s and Parkinson’s diseases. It enhances cholinergic function by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers following single oral dose administration.
References
Lalli, S, & Albanese, A (2008). Rivastigmine in Parkinson's disease dementia. Expert review of neurotherapeutics 8(8) 1181–1188. DOI:10.1586/14737175.8.8.1181 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18671661
Hossain, M, et al., & Cutler, NR (2002). Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clinical pharmacokinetics 41(3) 225–234. DOI:10.2165/00003088-200241030-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11929322
Mercier, F, et al., & Appel-Dingemanse, S (2007). Rivastigmine exposure provided by a transdermal patch versus capsules. Current medical research and opinion 23(12) 3199–3204. DOI:10.1185/030079908X253438 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18001519
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)